Novartis CEO Daniel Vasella talks about his seven-year effort, which is now bearing fruit, to overhaul Novartis' R&D by focusing on rare diseases for the next blockbuster drugs
The federal government should help finance the expansion of U.S. health coverage by taxing products, such as sugary soft drinks, that contribute to obesity and other chronic health conditions. Pro or Con?
CEO Dan Vasella's growth mantra for Novartis is follow the science, not the financials
Some global companies, from Fiat to Oracle to Toys 'R' Us, are taking advantage of the downturn by making gutsy moves that are likely to pay off later
Automated innovation—relying on computers to roll out new products—flopped at first. Now it's come back as a cost-cutting tool for hard times
"I was looking forward to upgrading from Treo 650. I went to the Sprint store. None in stock. Best Buy? None in stock. Money burning a hole in my pocket and I can't spend ."
Tell Us: Did iPhone Steal Palm's Thunder?
If this sounds warm and fuzzy, keep in mind that it's also about winning
Nations are constructing lavish science parks, often with big-city amenities, to gain a competitive edge in the global economy